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Abstract
Objectives: To determine the prevalence of type 2 diabetes mellitus, in three groups of Peruvian adults, using fasting
glucose and glycosylated hemoglobin (A1C).
Methodology/Principal Findings: This study included adults from the PERU MIGRANT Study who had fasted $8 h. Fasting
glucose $126 mg/dL and A1C$6.5% were used, separately, to define diabetes. Subjects with a current diagnosis of
diabetes were excluded. 964 of 988 subjects were included in this analysis. Overall, 0.9% (95%CI 0.3–1.5) and 3.5% (95%CI
2.4–4.7) had diabetes using fasting glucose and A1C criteria, respectively. Compared to those classified as having diabetes
using fasting glucose, newly classified subjects with diabetes using A1C (n=25), were older, poorer, thinner and more likely
to come from rural areas. Of these, 40% (10/25) had impaired fasting glucose (IFG).
Conclusions: This study shows that the use of A1C as diagnostic criteria for type 2 diabetes mellitus identifies people of
different characteristics than fasting glucose. In the PERU MIGRANT population using A1C to define diabetes tripled the
prevalence; the increase was more marked among poorer and rural populations. More than half the newly diagnosed
people with diabetes using A1C had normal fasting glucose.
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Introduction
Diabetes is a global problem [1], however there is limited
information about this condition in Latin America [2,3]. Tradi-
tionally, for epidemiological studies, diabetes has been defined using
fasting plasma glucose $126 mg/dL ($7 mmol/L) [4,5]. In 2009,
the American Diabetes Association suggested that glycosylated
hemoglobin (A1C) could be used as a diagnostic tool for diabetes
[6]. In the United States, Selvin et al. [7] found individuals with
A1C values of 6% or higher were at higher risk of developing
diabetes and that A1C was a marker for cardiovascular disease.
These results suggest that A1C may be a superior marker to fasting
glucose for characterizing long term diabetes risk. However,
recently published findings indicate that A1C levels are higher in
black than white persons across the full spectrum of glycemia thus
potentially limiting the widespread adoption of A1C to screen for
glucose intolerance, indicate the risk for complications, measure
quality of care, and evaluate disparities in health [8].
In low-and- middle income countries (LMIC), the increased
burden of chronic diseases is largely driven by internal migration
and urbanization. The dearth of population-based data on
hyperglycemia and diabetes [2], as well as on disease progression
and mortality limits our ability to intervene appropriately.
Furthermore, ethnic differences have been described in A1C
levels, [8,9,10,11] which may affect the appropriateness of A1C in
LMIC settings.
To our knowledge the impact of using A1C as a diagnostic
criterion for diabetes in LMIC has yet to be investigated. Within
the Peru MIGRANT study [12], we compared A1C and fasting
glucose for the diagnosis of diabetes in rural, rural-to-urban
migrants and an urban population. The specific objective was to
estimate the prevalence of type 2 diabetes mellitus in adults using
fasting glucose and A1C.
Materials and Methods
Ethics statement
Ethical approval for this protocol was obtained from ethics
committees at Universidad Peruana Cayetano Heredia in Peru
and London School of Hygiene and Tropical Medicine in the UK.
Written informed consent was obtained from all participants
involved in the study.
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Cross-sectional survey conducted in 2007–2008 of three
population-based groups: rural, people born in Ayacucho who
had always lived in a rural environment; rural-to-urban migrants,
people born in Ayacucho who migrated from rural to urban areas
and currently living in Lima; and, urban, people born and
currently living in Lima, specifically in the area called ‘‘Pampas de
San Juan de Miraflores’’ in a southern district of Lima. Details of
the study design have been reported elsewhere [12]. A single-stage
random sampling method was used in all groups. In the rural site,
the district of San Jose de Secce in Ayacucho, a census was
conducted in mid 2007. The sampling frame for the urban group
was derived from the local census, conducted in year 2000, which
was updated in 2006 to identify all those who referred to have
been born in the department of Ayacucho and were currently
living in Lima. From these updated censuses, the sampling frame
of adults $30years-old was 398, 1785, and 4621 individuals for
the rural, rural-to-urban migrants and urban groups, respectively
[12].
Study variables
Data were collected through questionnaires (demographics,
migration and medical history), a physical examination and blood
collection. Fasting glucose, fasting insulin and A1C were measured
in plasma, serum and whole blood, respectively. Insulin resistance
(HOMA-IR) was calculated using the HOMA calculator [13],
excluding those with diabetes.
Plasma glucose was measured using an enzymatic colorimetric
method (GOD-PAP, Modular P-E/Roche- Cobas, Germany),
serum insulin using electrochemiluminescence (Modular P-E/
Table 1. Characteristics of the PERU MIGRANT population according to A1C and fasting glucose levels.
A1C,6.5%* A1C$6.5%
All Glucose,126** Glucose,126** Glucose$126** p-value
n=964 n=930 n=25 n=9
Demographic and socioeconomic
Age, years (mean, SD)
¥ 47.9 (12.1) 47.5 (11.8) 58.4 (15.7) 55.7 (11.1) ,0.001
Men (%, 95%CI)
{ 47.2 (44–50.4) 47.4 (44.2–50.6) 40 (19.4–60.6) 44.4 (3.9–85) 0.78
Socioeconomically deprived (%, 95%CI)
1,¥ 30.7 (27.8–33.6) 29.6 (26.6–32.5) 68 (48.4–87.7) 44.4 (3.9–85) ,0.005
Cardiovascular risk factors
Hemoglobin, g/dL (mean, SD)
¥ 14.2 (1.6) 14.2 (1.7) 14.7 (1.5) 14.7 (1.7) 0.16
Anemia (%, 95%CI)
2,{ 7.9 (6.2–9.6) 8.1 (6.3–9.8) 4.0 (0.0–12.3) – 0.86
BMI, Kg/m
2 (mean, SD)
¥ 26.5 (4.6) 26.4 (4.5) 25.7 (5.9) 30.9 (6.3) 0.02
Current smoking (%, 95%CI)
3,{ 11 (9–13) 11.1 (9.1–13.1) 8.0 (0.0–19.4) 11.1 (0.0–36.7) 0.99
Low physical activity (%, 95%CI)
4,{ 26.0 (23.3–28.8) 26.1 (23.3–28.9) 20.8 (3.3–38.4) 33.3 (0.0–71.8) 0.76
Systolic blood pressure, mmHg (mean, SD)
¥ 121.6 (18.6) 121.1 (18.1) 133.1 (25.7) 141.7 (28.7) ,0.01
Diastolic blood pressure, mmHg (mean, SD)
¥ 72.8 (9.9) 72.6 (9.7) 79.7 (12.7) 83.2 (12.4) ,0.001
Total cholesterol, mg/dL (mean, SD)
¥ 184.1 (40.8) 183.5 (40.0) 185.0 (56.5) 238.7 (41.7) ,0.01
HDL-cholesterol, mg/dL (mean, SD)
¥ 44.1 (11.6) 44.1 (11.5) 43.8 (11.8) 45.7 (20.7) 0.79
LDL-cholesterol, mg/dL (mean, SD)
¥ 110.2 (34.4) 110.0 (33.9) 108.1 (45.2) 142.8 (38.1) 0.03
Tryglicerides, mg/dL (mean, SD)
¥ 152.4 (93.3) 150.5 (91.4) 165.9 (90.4) 304.9 (161.8) ,0.01
Metabolic markers
Fasting glucose, mg/dL (median, IQR)
¥ 85 (79–91) 85 (79–90) 96 (84–112) 148 (134–256) ,0.001
A1C, % (median, IQR)
¥ 5.6 (5.4–5.9) 5.6 (5.3–5.8) 6.7 (6.5–7.0) 8.2 (7.3–12.7) ,0.001
Insulin, mIU/mL (median, IQR)
¥ 6.0 (3.3–9.9) 5.9 (3.4–9.8) 5.2 (1.9–12.6) 9.1 (6.9–17.7) 0.07
HOMA-IR (median, IQR)
5,¥ 0.8 (0.4–1.3) 0.8 (0.4–1.3) 0.7 (0.3–1.7) 1.6 (1.1–2.7) 0.01
Impaired fasting glucose
IFG ADA – %, (95%CI)
6,{ 7.4 (5.8–9.2) 6.6 (5.1–8.4) 40 (21.1–61.3) – ,0.001
IFG WHO – %, (95%CI)
{ 1.5 (0.8–2.4) 0.8 (0.3–1.6) 28 (12.1–49.4) – ,0.001
Notes:
*No cases matched the criteria for the group A1C,6.5% and Glucose$126 mg/dL.
**Unit of fasting blood glucose in mg/dL.
1At least 2 or more socioeconomic deprivations from four areas: educational level (none or incomplete primary education), household income (less thanU S D$150
dollars per month) and asset’s possession (lowest tertile of possessions weighted asset index).
2Anemia was defined as having hemoglobin ,12 among females or ,13 among males.
3Current smoking was defined as having smoked within the last six months and a lifetime total of more than 100 cigarettes.
4Low physical activity was defined as those participants with ,600 MET minutes per week. Information on physical activity was available for 956/964 subjects.
5Information for HOMA-IR was available on 953/964 subjects.
6ADA’s IFG, fasting glucose$100 and ,126 mg/dL. WHO’s IFG, fasting glucose$110 and ,126 mg/dL.
{p-values were obtained comparing between the three groups using Fisher’s exact test.
¥p-values were obtained comparing between the three groups using Kruskal-Wallis test.
doi:10.1371/journal.pone.0018069.t001
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chromatography (D10- BIORAD, Germany), which is traceable to
the Diabetes Control and Complications Trial reference study as
certified by National Glycohemoglobin Standardization Program
(NGSP). All samples were analyzed in a single facility. For quality
assurance, the quality of assays was checked with regular external
standards and internal duplicate assays and monitored by BioRad
(www.biorad.com).
The prevalence (95% confidence intervals [CIs]) of diabetes was
determined using the American Diabetes Association (ADA)
($126 mg/dL) [5] cut-offs for fasting glucose and $6.5% for
A1C [6]. Participants that were aware of their diabetes condition
were excluded from the analysis. IFG was defined using ADA’s
($100 and ,126 mg/dL) and WHO’s ($110 and ,126 mg/dL)
cut-offs for fasting glucose.
Statistical analysis
The k statistic was calculated to measure agreement between
the two definitions [14]. Comparison of proportions and medians
between groups were evaluated through Fisher’s exact test and
Kruskal-Wallis tests. Data were analyzed using Stata 11 (Stata
Corporation LP, College Station, TX).
Results
A total of 988/989 participants, aged 30–92 years, enrolled in
this study had complete information for both fasting glucose and
A1C. Twenty-four subjects who were aware of their diabetes
condition were excluded from the analysis. Using fasting glucose
9/964 (0.9%; 95%CI 0.3–1.5) were classified as having diabetes,
whereas 34/964 (3.5%; 95%CI 2.4–4.7) had diabetes using A1C.
Of those with fasting glucose $126 mg/dL, none had
A1C,6.5%. Fair agreement existed between these diagnostic
criteria (k 0.41; 95%CI 0.23–0.59).
The profile of those newly classified diabetes cases, where A1C
was $6.5% but fasting glucose was ,126 mg/dL (n=25), were
older, more socioeconomically deprived and had higher blood
pressure levels (Table 1). The newly diagnosed group was not
different from the non-diabetes group in terms of hemoglobin
levels, anemia, BMI, smoking, physical activity, cholesterol and
Table 2. Characteristics of participants newly classified as diabetes cases based on ADA and WHO’s cut-offs for IFG.
ADA’s IFG cut-off WHO’s IFG cut-off
$100 and ,126 mg/dL $110 and ,126 mg/dL
No IFG IFG p-value No IFG IFG p-value
n=15/25 n=10/25 n=18/25 n=7/25
Demographic and socioeconomic
Age, years (mean, SD)
¥ 58.7 (14.0) 58 (18.6) 0.87 57.7 (14.5) 60.3 (19.4) 0.65
Men (%, 95%IC)
{ 33.3 (11.8–61.6) 50 (18.7–81.3) 0.44 27.8 (9.6–53.4) 71.4 (29–96.3) 0.08
Socioeconomically deprived (%, 95%CI)
1,{ 86.7 (59.5–98.3) 40 (12.2–73.8) 0.03 83.3 (58.6–96.4) 28.6 (3.7–71) 0.02
Cardiovascular risk factors
Hemoglobin, g/dL (mean, SD)
¥ 14.7 (1.6) 14.8 (1.3) 0.96 14.8 (1.6) 14.6 (1.1) 0.81
Anemia (%, 95%CI)
2,{ 6.7 (0.0–21.0) 0.0 (0.0–30.8) 0.60 5.6 (0.0–17.3) 0.0 (0.0–41.0) 0.72
BMI, Kg/m
2 (mean, SD)
¥ 24.2 (5.1) 27.9 (6.6) 0.11 24.1 (4.9) 29.6 (6.8) 0.04
Current smoking (%, 95%CI)
3,{ 6.7 (0.2–31.9) 10.0 (2.5–44.5) 0.99 5.6 (0.1–27.3) 14.3 (0.4–57.9) 0.49
Low physical activity (%, 95%CI)
4,{ 26.7 (7.8–55.1) 11.1 (2.8–48.3) 0.62 22.2 (6.4–47.6) 16.7 (0.4–64.1) 0.99
Systolic blood pressure, mmHg (mean, SD)
¥ 122.8 (15.5) 148.5 (30.7) 0.04 123.5 (14.3) 157.7 (32.8) 0.02
Diastolic blood pressure, mmHg (mean, SD)
¥ 74.8 (9.9) 86.9 (13.3) 0.04 75.3 (9.4) 90.9 (13.7) 0.02
Total cholesterol, mg/dL (mean, SD)
¥ 171.6 (49.4) 205.2 (63.0) 0.16 178.6 (61.1) 201.6 (42.2) 0.24
HDL-cholesterol, mg/dL (mean, SD)
¥ 47.1 (12.5) 38.7 (9.1) 0.10 44.6 (13.5) 41.6 (5.6) 0.49
LDL-cholesterol, mg/dL (mean, SD)
¥ 96.4 (33.8) 125.6 (55.8) 0.13 103.9 (50.2) 118.8 (29.3) 0.15
Tryglicerides, mg/dL (mean, SD)
¥ 140.3 (79.6) 204.4 (96.0) 0.05 150.4 (76.0) 205.9 (117.3) 0.25
Metabolic markers
Fasting glucose, mg/dL (median, IQR)
¥ 85 (80–93) 116 (109–119) ,0.001 85.5 (82–97) 118 (116–120) ,0.001
A1C, % (median, IQR)
¥ 6.6 (6.5–7.1) 6.8 (6.6–7) 0.30 6.7 (6.5–7.1) 6.8 (6.6–6.9) 0.60
Insulin, mIU/mL (median, IQR)
¥ 2.0 (1.5–6.4) 16.3 (5.3–21.5) 0.002 3.5 (1.7–6.4) 16.4 (8.6–21.9) 0.003
HOMA-IR (median, IQR)
5,¥ 0.3 (0.2–0.9) 2.2 (0.7–2.9) 0.001 0.5 (0.2–0.9) 2.2 (1.2–3.0) 0.003
Notes:
1At least 2 or more socioeconomic deprivations from four areas: educational level (none or incomplete primary education), household income (less thanU S D$150
dollars per month) and asset’s possession (lowest tertile of possessions weighted asset index).
2Anemia was defined as having hemoglobin ,12 among females or ,13 among males.
3Current smoking was defined as having smoked within the last six months and a lifetime total of more than 100 cigarettes.
4Low physical activity was defined as those participants with ,600 MET minutes per week. Information on physical activity was available for 956/964 subjects.
5Information for HOMA-IR was available on 953/964 subjects.
{p-values were obtained comparing between the three groups using Fisher’s exact test.
¥p-values were obtained comparing between the three groups using Kruskal-Wallis test.
doi:10.1371/journal.pone.0018069.t002
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using WHO’s IFG definition (Table 1).
The profile of those with raised A1C but low fasting glucose
using standard IFG classifications is shown in Table 2. Partic-
ipants with raised A1C and IFG were more likely of not being
socioeconomically deprived and to have higher BMI, higher blood
pressure, higher insulin and higher HOMA-IR.
The distributions of new classification of diabetes by migration
status are shown in Table 3. There were more newly diagnosed
diabetes cases, as defined by A1C, in the rural group (6.5%)
compared to the migrant and urban groups (1.2% and 2.7%,
respectively).
Discussion
When applied to a sample of Peruvian migrant and non-
migrant population, the new recommendation by the Internation-
al Expert Committee [6] to use A1C to diagnose diabetes would
result in a tripling of the prevalence of diabetes. Our findings
suggest that forty percent of people who would be newly labeled as
having diabetes are likely to have normal fasting glucose. The
increased prevalence of diabetes will be more marked among
lower socioeconomic groups and among rural populations, and no
evidence of differences in levels of smoking and anemia we
observed. Our study also identified that those that qualify as
diabetics based on A1C despite having normal fasting glucose
levels were older. While the International Expert Committee [6]
acknowledges that A1C may increase with age based on Pani’s
work [15], it does not suggest age-specific values in diagnostic
scheme. Our results would suggest that this observation deserves
further scrutiny. Further investigation and follow-up of individuals
with raised A1C in rural and high altitude populations is necessary
before adaptation of the new recommendations in Peru.
Our observations regarding the agreement between the two
criteria are similar to a recent study from US adult population
where, overall , A1C$6.5% showed fair agreement (k 0.40) with
fasting glucose for diagnosing diabetes [16]. Such agreement
values would mean that the test is only moderately good for
positive diagnosis or ruling-in disease [14,17].
Over half of the subjects classified as diabetes cases using A1C,
would be considered normal using fasting glucose. The group with
elevated A1C but normal fasting glucose was older and
socioeconomically deprived, however did not exhibit any of the
other classic risk factors for metabolic and cardiovascular disease
other than higher blood pressure levels. Using A1C also classified
more people living in rural areas as diabetes cases; these results
may indicate true disease prevalence in rural areas, reflect genetic
differences, or the effects of altitude on A1C. Indeed, a recent
genome-wide association study by Soranzo et al. showed that most
gene variants that affect A1C levels are likely to do so via
erythrocyte biology rather than glycaemic pathways [18]. As for
altitude, one of its known effects is hyperemia, yet no differences in
hemoglobin levels and anemia were observed in the groups of
interest.
Further studies are needed to confirm our findings given their
major implications in low income settings, where rural areas will
struggle to manage chronic conditions with limited resources. A1C
is notlimitations-free and, at the individuallevel, these arerelated to
hemoglobin traits, red cell turnover, age and racial disparities.
Further limitations with the test itself do exist, particularly related to
their high cost and need of standardization [6]. In the present study,
despitetherelativelysmallnumberofdiabetescases,wewereableto
detect differences between the groups, that is, the study was not
underpowered to evaluate the differences under scrutiny.
Our interpretations may be limited by the cross-sectional nature
of the study; we cannot infer the differences or relationships
observed are causal without appropriate longitudinal data in our
population. The study could have been strengthened with oral
glucose tolerance test (OGTT) results. The DECODE Study
Group has reported that, compared to fasting glucose, the use of
this gold standard would yield a true prevalence 30 to 60% higher
[19,20,21]. However, even our estimates obtained using fasting
glucose had been 30–60% higher through use of an OGTT, this
increased prevalence would still be much lower than the
prevalence of diabetes we identified through using A1C. It is
unlikely that these results are due to inadequate fasting, if this was
the case, we would have observed cases where fasting glucose was
elevated but A1C was normal.
Our findings may have major implications for determining the
burden of diabetes in LMIC. The increased prevalence of diabetes
using the A1C cut-offs, could potentially increase health care costs
and may place patients at risk of unnecessary drug-related side-
effects. While there is evidence from the United States that
elevated A1C is linked to CVD mobility [7], further studies are
Table 3. Characteristics of population according to A1C and fasting glucose levels by migration status.
A1C,6.5% A1C$6.5% p-value
Glucose,126* Glucose,126* Glucose$126*
Population distribution by study group (%, 95%CI)
{ n=930 n=25 n=9
Rural (n=200) 93 (88.5–96.1) 6.5 (3.5–10.9) 0.5 (0.0–2.8) 0.002
Migrant (n=575) 97.9 (94.6–98.9) 1.2 (0.5–2.5) 0.9 (0.3–2.0)
Urban (n=189) 95.8 (91.8–98.1) 2.7 (0.9–6.1) 1.6 (0.3–4.6)
Migration patterns (migrant population only) n=571** n=7 n=5
Age at migration (median, IQR)
¥ 14 (10–17) 17 (11–24) 18 (17–25) 0.02
Years lived in urban area (median, IQR)
¥ 31 (25–39) 35 (25–37) 38 (31–38) 0.87
Lifetime exposure to urban area (%, 95%CI)
¥ 69.6 (59.1–77.8) 71.6 (51.4–78.7) 60.3 (55.4–67.9) 0.31
Notes:
*Unit of fasting blood glucose in mg/dL.
**n=571 for age at migration and n=546 for other migration classifications.
{p-values were obtained comparing between the three groups using Fisher’s exact test.
¥p-values were obtained comparing between the three groups using Kruskal-Wallis test.
doi:10.1371/journal.pone.0018069.t003
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diabetic complications and/or the development of cardiovascular
disease, before A1C is recommended as a diagnostic criterion for
LMIC. In addition, it needs to be determined whether it is
appropriate to intervene on A1C in these settings, independently
of glucose levels.
Conclusions
In conclusion using A1C to define diabetes tripled its
prevalence; the increase being more marked among poorer and
rural populations. This study suggests the use of A1C as diagnostic
criteria for diabetes may have major implications for the burden of
disease in LMIC.
Acknowledgments
Our special gratitude to various colleagues at Universidad Peruana
Cayetano Heredia and A.B. PRISMA in Lima, Peru and several others in
the UK, as well as to the staff and the team of fieldworkers that contributed
to different parts of this study. The authors declare that they have no
competing interests.
Author Contributions
Conceived and designed the experiments: JJM. Analyzed the data: AB-O
SS. Wrote the manuscript: JJM. Critical input to interpretation of results:
GM RHG LS. Participated in the design of the study and actively
supported the fieldwork phase of the study: RHG LS.
References
1. Zimmet P, Alberti KGMM, Shaw J (2001) Global and societal implications of
the diabetes epidemic. Nature 414: 782–787.
2. International Diabetes Federation (2009) Diabetes atlas. Brussels: International
Diabetes Federation.
3. Miranda JJ, Kinra S, Casas JP, Davey Smith G, Ebrahim S (2008) Non-
communicable diseases in low- and middle-income countries: context,
determinants and health policy. Trop Med Int Health 13: 1225–1234.
4. World Health Organization (1999) Definition, diagnosis and classification of
diabetes mellitus and its complications. Geneva: World Health Organization.
5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
(2003) Follow-up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care
26: 3160–3167.
6. The International Expert Committee (2009) International Expert Committee
Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes
Care 32: 1327–1334.
7. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, et al. (2010)
Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic
Adults. N Engl J Med 362: 800–811.
8. Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, et al. (2010)
Glucose-Independent, Black–White Differences in Hemoglobin A1c Levels.
Annals of Internal Medicine 152: 770–777.
9. Kirk JK, D’Agostino RB, Bell RA, Passmore LV, Bonds DE, et al. (2006)
Disparities in HbA1c Levels Between African-American and Non-Hispanic
White Adults With Diabetes. Diabetes Care 29: 2130–2136.
10. Gama R, Likhari T (2009) Diagnosis of diabetes. Haemoglobin A1c: ethnic
differences apply to the UK. BMJ 339: b5648.
11. Herman WH, Dungan KM, Wolffenbuttel BHR, Buse JB, Fahrbach JL, et al.
(2009) Racial and Ethnic Differences in Mean Plasma Glucose, Hemoglobin
A1c, and 1,5-Anhydroglucitol in Over 2000Patients with Type 2Diabetes. J Clin
Endocrinol Metab 94: 1689–1694.
12. Miranda JJ, Gilman RH, Garcia HH, Smeeth L (2009) The effect on
cardiovascular risk factors of migration from rural to urban areas in Peru:
PERU MIGRANT Study. BMC Cardiovascular Disorders 9: 23.
13. Wallace TM, Levy JC, Matthews DR (2004) Use and Abuse of HOMA
Modeling. Diabetes Care 27: 1487–1495.
14. Landis JR, Koch GG (1977) The measurement of observer agreement for
categorical data. Biometrics 33: 159–174.
15. Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, et al. (2008) Effect of
aging on A1C levels in individuals without diabetes: evidence from the
Framingham Offspring Study and the National Health and Nutrition
Examination Survey 2001–2004. Diabetes Care 31: 1991–1996.
16. Carson AP, Reynolds K, Fonseca VA, Muntner P (2010) Comparison of A1C
and Fasting Glucose Criteria to Diagnose Diabetes Among U.S. Adults.
Diabetes Care 33: 95–97.
17. Gilchrist JM (2009) Weighted 262 kappa coefficients: recommended indices of
diagnostic accuracy for evidence-based practice. J Clin Epidemiol 62:
1045–1053.
18. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, et al. (2010) Common
variants at 10 genomic loci influence hemoglobin A(C) levels via glycemic and
nonglycemic pathways. Diabetes 59: 3229–3239.
19. The DECODE Study Group (1998) Will new diagnostic criteria for diabetes
mellitus change phenotype of patients with diabetes? Reanalysis of European
epidemiological data. BMJ 317: 371–375.
20. The DECODE Study Group (1999) Glucose tolerance and mortality:
comparison of WHO and American Diabetes Association diagnostic criteria.
Lancet 354: 617–621.
21. The DECODE Study Group (2003) Is the Current Definition for Diabetes
Relevant to Mortality Risk From All Causes and Cardiovascular and
Noncardiovascular Diseases? Diabetes Care 26: 688–696.
A1C in Peru
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e18069